• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病基因 SNCA、LRRK2、VPS35 的基因型-表型关系:MDSGene 系统评价。

Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.

机构信息

Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.

The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.

出版信息

Mov Disord. 2018 Dec;33(12):1857-1870. doi: 10.1002/mds.27527. Epub 2018 Oct 24.

DOI:10.1002/mds.27527
PMID:30357936
Abstract

This comprehensive MDSGene review is devoted to the three autosomal-dominant PD forms: PARK-SNCA, PARK-LRRK2, and PARK-VPS35. It follows MDSGene's standardized data extraction protocol, screened a total of 2,972 citations, and is based on fully curated phenotypic and genotypic data on 937 patients with dominantly inherited PD attributed to 44 different mutations in SNCA, LRRK2, or VPS35. All of these data are also available in an easily searchable online database (www.mdsgene.org), which additionally provides descriptive summary statistics on phenotypic and genetic data. Despite the high degree of missingness of phenotypic features and unsystematic reporting of genotype data in the original literature, the present review recapitulates many of the previously described findings including later onset of disease (median age at onset: ∼49 years) compared to recessive forms of PD of an overall excellent treatment response. Our systematic review validates previous reports showing that SNCA mutation carriers have a younger age at onset compared to LRRK2 and VPS35 (P < 0.001). SNCA mutation carriers often have additional psychiatric symptoms, and although not exclusive to only LRRK2 or VPS35 mutation carriers, LRRK2 mutation carriers have a typical form of PD, and, lastly, VPS35 mutation carriers have good response to l-dopa. © 2018 International Parkinson and Movement Disorder Society.

摘要

这篇全面的 MDSGene 综述致力于三种常染色体显性 PD 形式:PARK-SNCA、PARK-LRRK2 和 PARK-VPS35。它遵循 MDSGene 的标准化数据提取协议,共筛选了 2972 条引文,并基于 937 名常染色体显性遗传 PD 患者的完全编目表型和基因型数据,这些患者归因于 SNCA、LRRK2 或 VPS35 中的 44 个不同突变。所有这些数据也可在一个易于搜索的在线数据库(www.mdsgene.org)中获得,该数据库还提供了表型和遗传数据的描述性汇总统计信息。尽管原始文献中表型特征的缺失程度很高,基因型数据的报告也不系统,但本综述总结了许多先前描述的发现,包括与 PD 的隐性形式相比,疾病的发病年龄较晚(发病中位年龄:约 49 岁),整体治疗反应良好。我们的系统综述验证了先前的报告,表明与 LRRK2 和 VPS35 相比,SNCA 突变携带者的发病年龄更早(P<0.001)。SNCA 突变携带者通常有额外的精神症状,尽管并非仅存在于 LRRK2 或 VPS35 突变携带者中,但 LRRK2 突变携带者有典型的 PD 形式,最后,VPS35 突变携带者对 l-多巴有良好的反应。©2018 国际帕金森病和运动障碍学会。

相似文献

1
Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.帕金森病基因 SNCA、LRRK2、VPS35 的基因型-表型关系:MDSGene 系统评价。
Mov Disord. 2018 Dec;33(12):1857-1870. doi: 10.1002/mds.27527. Epub 2018 Oct 24.
2
Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.常染色体显性帕金森病:巴西LRRK2、SNCA、VPS35和GBA基因突变的发生率
Neurosci Lett. 2016 Dec 2;635:67-70. doi: 10.1016/j.neulet.2016.10.040. Epub 2016 Oct 21.
3
MDSGene: Closing Data Gaps in Genotype-Phenotype Correlations of Monogenic Parkinson's Disease.MDSGene:填补单基因帕金森病基因型-表型相关性中的数据空白。
J Parkinsons Dis. 2018;8(s1):S25-S30. doi: 10.3233/JPD-181505.
4
Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review.帕金森病基因 Parkin、PINK1、DJ1 的基因型-表型关系:MDSGene 系统评价。
Mov Disord. 2018 May;33(5):730-741. doi: 10.1002/mds.27352. Epub 2018 Apr 11.
5
The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.帕金森病 VPS35[D620N]突变增强了小鼠和人类中 LRRK2 介导的 Rab 蛋白磷酸化。
Biochem J. 2018 Jun 6;475(11):1861-1883. doi: 10.1042/BCJ20180248.
6
α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.α-突触核蛋白(SNCA)而非动力蛋白 3(DNM3)影响西班牙富亮氨酸重复激酶 2(LRRK2)帕金森病的发病年龄。
Mov Disord. 2018 Apr;33(4):637-641. doi: 10.1002/mds.27295. Epub 2018 Feb 23.
7
SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.SNCA 而非 DNM3 和 GAK 改变了中国人群 LRRK2 相关帕金森病的发病年龄。
J Neurol. 2019 Jul;266(7):1796-1800. doi: 10.1007/s00415-019-09336-7. Epub 2019 Apr 30.
8
Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review.遗传形式帕金森病的治疗方法:系统文献回顾。
J Neuromuscul Dis. 2021;8(3):341-356. doi: 10.3233/JND-200598.
9
Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey.LRRK2 和 SNCA 在土耳其常染色体显性遗传帕金森病中的作用。
Parkinsonism Relat Disord. 2018 Mar;48:34-39. doi: 10.1016/j.parkreldis.2017.12.007. Epub 2017 Dec 9.
10
Analysis of the genetic variability in Parkinson's disease from Southern Spain.西班牙南部帕金森病的遗传变异性分析。
Neurobiol Aging. 2016 Jan;37:210.e1-210.e5. doi: 10.1016/j.neurobiolaging.2015.09.020. Epub 2015 Oct 8.

引用本文的文献

1
Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.重新审视帕金森病的定义和分类:来自两个新兴生物学框架的见解。
J Neural Transm (Vienna). 2025 Sep 4. doi: 10.1007/s00702-025-03013-y.
2
Exploring the Neuroprotective Role of Selenium: Implications and Perspectives for Central Nervous System Disorders.探索硒的神经保护作用:对中枢神经系统疾病的影响及展望
Exploration (Beijing). 2025 Apr 1;5(4):e20240415. doi: 10.1002/EXP.20240415. eCollection 2025 Aug.
3
The Global Landscape of Genetic Variation in Parkinson's disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance.
帕金森病遗传变异的全球格局:对既定疾病基因及其转化相关性的多血统见解
medRxiv. 2025 Jul 11:2025.07.08.25330815. doi: 10.1101/2025.07.08.25330815.
4
The promise of gene therapy in common types of dementia.基因疗法在常见类型痴呆症中的前景。
Bioimpacts. 2025 Apr 21;15:30795. doi: 10.34172/bi.30795. eCollection 2025.
5
The role of dopaminergic medication and specific pathway alterations in idiopathic and -mediated Parkinson's disease.多巴胺能药物及特定通路改变在特发性和[此处原文似乎不完整,推测可能是“继发性”之类的词]帕金森病中的作用
Sci Adv. 2025 May 16;11(20):eadp7063. doi: 10.1126/sciadv.adp7063. Epub 2025 May 14.
6
Mitochondrial Dysfunction in Genetic and Non-Genetic Parkinson's Disease.遗传和非遗传帕金森病中的线粒体功能障碍
Int J Mol Sci. 2025 May 7;26(9):4451. doi: 10.3390/ijms26094451.
7
Genotype-Phenotype Relations for the Dystonia-Parkinsonism Genes , , , , and : MDSGene Systematic Review.肌张力障碍-帕金森综合征相关基因、、、和的基因型-表型关系:MDS基因系统评价
Int J Mol Sci. 2025 Apr 25;26(9):4074. doi: 10.3390/ijms26094074.
8
Genetic Sketch of Parkinson's Disease in India.印度帕金森病的基因概述。
Ann Indian Acad Neurol. 2025 Jul 1;28(4):495-504. doi: 10.4103/aian.aian_1021_24. Epub 2025 May 7.
9
Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery.神经退行性疾病中的蛋白激酶:当前认识及对药物研发的意义
Signal Transduct Target Ther. 2025 May 7;10(1):146. doi: 10.1038/s41392-025-02179-x.
10
Genetic risk for neurodegenerative conditions is linked to disease-specific microglial pathways.神经退行性疾病的遗传风险与疾病特异性小胶质细胞途径有关。
PLoS Genet. 2025 Apr 9;21(4):e1011407. doi: 10.1371/journal.pgen.1011407. eCollection 2025 Apr.